Biohaven Pharma (BHVN) Misses Q4 EPS by 11c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($1.71), $0.11 worse than the analyst estimate of ($1.60).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
• BeWhere acquires SecureQuip Systems for $789,000 in cash